A biochemical and functional assessment of monocyte phosphodiesterase activity in healthy and asthmatic subjects

Pulmonary Pharmacology and Therapeutics

Volumn 13, Issue 5, 2000, Pages 231-239

  Landells, L J ^a   Spina, D ^a,b   Souness, J E ^a,c   O'Connor, B J ^a,b   Page, C P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Aventis Pharmaceuticals   (United Kingdom)

Author keywords

Asthma; cAMP; Monocyte; Phosphodiesterase; TNF

Indexed keywords

PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; SIGUAZODAN; THEOPHYLLINE;

ALLERGY; ARTICLE; ASTHMA; BLOOD SAMPLING; CONCENTRATION RESPONSE; ENZYME ACTIVITY; FUNCTIONAL ASSESSMENT; HUMAN; HUMAN CELL; INFLAMMATORY CELL; MAST CELL DEGRANULATION; MONOCYTE; MONONUCLEAR CELL; PRIORITY JOURNAL;

EID: 0033737479     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1006/pupt.2000.0248     Document Type: Article

References (43)

1. Atopic dermatitis - The skin manifestation of atopy
2. Role of T cells in asthma
3. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma
4. Anti-inflammatory effects of theophylline and selective phosphodiesterase inhibitors
5. Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases
6. Regulation of cAMP and cGMP signaling: New phosphodiesterases and new functions
7. Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: A possible mechanism for cyclic AMP-agonist hyporesponsiveness
8. Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes
9. Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: A comparative study
10. Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis
11. Induction of phosphodiesterases 3B, 4A4, 4D1, 4D2, and 4D3 in Jurkat T-cells and in human peripheral blood T-lymphocytes by 8-bromo-cAMP and Gs- coupled receptor agonists
12. Effect of PDE inhibitors on the proliferation of human peripheral blood mononuclear cells (HPBM) from mild asthmatics and normals
13. Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis
14. Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro
15. Patients with severe atopic dermatitis have activated circulating basophils
16. Evidence that defective interferon-gamma production in atopic dermatitis patients is due to intrinsic abnormalities
17. Decreased interferon gamma and increased interleukin-4 production in atopic dermatitis promotes IgE synthesis
18. Gamma-interferon production in atopic dermatitis shows differential modification by phosphodiesterase and prostaglandin inhibition
19. 2 control of T cell cytokine production is functionally related to the reduced lymphocyte proliferation in atopic dermatitis
20. Enhanced IL-4 production and IL-4 receptor expression in atopic dermatitis and their modulation by interferon-gamma
21. Altered prostaglandin E2 regulation of cytokine production in atopic dermatitis
22. 2-dependent
23. Overexpression of IL-10 in atopic dermatitis. Contrasting cytokine patterns with delayed-type hypersensitivity reactions
24. The role of the adrenergic system in allergy and bronchial hyperreactivity
25. The beta-adrenergic system and allergic bronchial asthma: Changes in lymphocyte beta-adrenergic receptor number and adenylate cyclase activity after an allergen-induced asthmatic attack
26. Reduced responsiveness of adenylate cyclase in alveolar macrophages from patients with asthma
27. Stimulation of cyclic AMP production in human alveolar macrophages induced by inflammatory mediators and beta-sympathicomimetic
28. Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages
29. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects
30. Increased respiratory burst and phosphodiesterase activity in alveolar eosinophils in chronic eosinophilic pneumonia
31. Cyclic adenosine monophosphate phosphodiesterase activity in peripheral blood mononuclear leukocytes from patients with atopic dermatitis: Correlation with respiratory atopy
32. Prolonged beta adrenoceptor stimulation up-regulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B
33. Isoprenaline induction of cAMP-phosphodiesterase in guinea-pig macrophages occurs in the presence, but not in the absence, of the phosphodiesterase type IV inhibitor rolipram
34. Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol
35. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors
36. Effects of nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors in antigen-induced cytokine gene expression in peripheral blood mononuclear cells
37. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors
38. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: Intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions
39. Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding
40. The granulocyte response to the phosphodiesterase inhibitor RO 20-1724 in asthma
41. Modulation of antigen- and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors
42. Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells
43. Phosphodiesterase type 4 inhibitors, but not glucocorticoids, are more potent in suppression of cytokine secretion by mononuclear cells from atopic than nonatopic donors